Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Pfizer Inc. (NYSE:PFE) is included among the 11 Innovative Dividend Stocks to Buy Now. The American multinational biotech ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson ...

Disclosure: None. This article is originally published at Insider Monkey.

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t ...

Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...